News Releases

Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

- NDA for maralixibat in Alagille syndrome (ALGS) granted priority review by U.S. FDA; PDUFA date is September 29, 2021 - Received additional $65.0 million in funding from Oberland Capital based on NDA acceptance - Commercial team hired in anticipation of U.S.

Mirum Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021

FOSTER CITY, Calif. --(BUSINESS WIRE)--Apr. 29, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced that the company will report financial results for the quarter ended March 31, 2021 on Thursday, May 6, 2021 . That same day, Mirum will host a conference call and audio webcast at

Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases

- CANbridge to lead development and commercialization in China ; expands rare disease pipeline - Mirum is entitled to receive up to an aggregate of $120.0 million in upfront and milestone payments, and significant double-digit tiered royalties FOSTER CITY, Calif. & BEIJING --(BUSINESS WIRE)--Apr.

Mirum Pharmaceuticals Receives Notice of Allowance for Methods of Use Patent for Maralixibat in Alagille Syndrome

- Methods of use patent expected to provide patent protection through 2040. FOSTER CITY, Calif. --(BUSINESS WIRE)--Apr. 26, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif. --(BUSINESS WIRE)--Apr. 12, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on April 12, 2021 , the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 118,800 shares of common stock to

Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis

- Mirum expands potential opportunities across rare disease pipeline - Vivet to lead pre-clinical development of its two gene therapy programs for PFIC3 and PFIC2 - Mirum gains option to license VTX-803 and VTX-802 FOSTER CITY, Calif. & PARIS--(BUSINESS WIRE)--Apr.

Mirum Pharmaceuticals Announces FDA Acceptance of New Drug Application and Priority Review for Maralixibat in Alagille Syndrome

- PDUFA action date is September 29, 2021 . - Priority review and Rare Pediatric Disease Designation granted. - FDA has indicated that advisory committee is not currently planned. FOSTER CITY, Calif. --(BUSINESS WIRE)--Mar. 29, 2021-- Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif. --(BUSINESS WIRE)--Mar. 10, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 10, 2021 , the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 114,800 shares of common stock to

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business Updates

- U.S. launch of maralixibat for Alagille syndrome (ALGS) planned for second half of 2021, if approved by FDA - Phase 2b programs initiated in Primary Sclerosing Cholangitis, Intrahepatic Cholestasis of Pregnancy and Biliary Atresia - Financial runway expected to support maralixibat launch in U.S.

Mirum Pharmaceuticals to Present at Upcoming Investor Conferences

FOSTER CITY, Calif. --(BUSINESS WIRE)--Feb. 22, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the company will participate in the following upcoming virtual investor conferences: SVB Leerink 10 th Annual Global Healthcare Conference Friday, February 26, 2021 at 3:40 p.m.

News Releases

News Releases

Header Menu